Details

Autor(en) / Beteiligte

• Zhang, Huiming
• Zhang, Zhongtao
• Xuan, Lixue
• Zheng, Shan
• Guo, Lei
• Zhan, Qimin
• Qu, Xiang
• Zhang, Baoning
• Wang, Yu
• Wang, Xiang
• Song, Yongmei

Titel

Evaluation of ER-α, ER-β1 and ER-β2 expression and correlation with clinicopathologic factors in invasive luminal subtype breast cancers

Ist Teil von

• Clinical & translational oncology, 2012-03, Vol.14 (3), p.225-231

Ort / Verlag

Milan: Springer Milan

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose Luminal subtype breast cancer is defined as oestrogen receptor (ER)- and/or progesterone receptor (PR)-positive breast cancer. We detected the expression of ER-α, ER-β1 and ER-β2 in the tissue samples of invasive luminal subtype breast cancer patients, evaluated the correlations between these ER statuses and prognosis, and tried to clarify whether the status of ER-α isoforms provides clinically useful information further to what is already provided by the traditional ER-α/PR assay. Methods The expression of ER-α, ER-β1 and ER-β2 in the paraffin-embedded sections of 162 invasive luminal subtype breast cancer patients was detected with an immunohistochemical staining method. With mid-long-term follow-up, the features of ER-α, ER-β1 and ER-β2 status and the correlations between clinical characteristics and the prognosis were analysed. Results ER-β1-positive status was correlated with PR ( rs =0.217, p <0.01). The median follow-up time was 92 months (range, 4-98 months). Univariate analysis suggested that ER-β1 status was significantly correlated to diseasefree survival (DFS) time (log rank=3.98, p =0.046), especially in patients with positive lymph nodes (log rank=6.20, p =0.013). In patients with smaller tumour size (≤20 mm), negative ER-β2 status was significantly correlated to overall survival time (log rank=3.87, p =0.049). Conclusions In invasive luminal subtype breast cancers, ER-β1 is correlated with good prognosis and could be regarded as one of the factors for evaluating DFS time, especially in lymph node-positive patients. There may be some interactions between ER-β1 and PR. In clinical practice, besides routine detection of ER-α and PR in invasive luminal subtype breast cancers, immunohistochemical staining of ER-β1 and ER-β2 should be considered in order to achieve more useful information. Further studies are needed to confirm our findings.